BIOCAUSE HEILEN PHARMA
30121110.152.73% ( +0.27 )
BIOCAUSE HEILEN PHARMA (301211)
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is invol...
- Open
- 9.89
- High
- 10.23
- Low
- 9.85
- Prev. Close
- 9.88
- Volume
- 46.70K
- Turnover
- 47.14M
- Avg Price
- 10.09
- Bid/Ask Ratio
- --
- Amplitude
- 3.85%
- 52wk High
- 16.89
- Volume Ratio
- 0.83
- Turnover Ratio
- 1.12%
News
- Zhitong · Oct 27, 2025 at 04:15 AM
BIOCAUSE HEILEN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 20.9334 million yuan, a decrease of 71.96%
- Zhitong · Oct 21, 2025 at 02:59 AM
BIOCAUSE HEILEN PHARMA: Febuxostat tablets have obtained a drug registration certificate
- Zhitong · Sep 16, 2025 at 03:01 AM
BIOCAUSE HEILEN PHARMA: Hydrochloride of Methoxychlorpromazine has received approval for the listing application of chemical raw materials
- Zhitong · Jul 31, 2025 at 03:31 AM
BIOCAUSE HEILEN PHARMA released its half-year performance, with a net profit attributable to the parent company of 18.5471 million yuan, a decrease of 72.92%
- Wallstreetcn · Jul 27, 2025 at 08:37 PM
Pharmaceutical and medical stocks continue to strengthen, with FENGYUAN PHARMACEUTICAL hitting the limit up, Hengrui Pharma rising over 7%, and Haisco, BIOCAUSE HEILEN PHARMA, Yatai pharm, and Yirui Biologics also following suit
- Zhitong · Jul 27, 2025 at 08:36 PM
The hepatitis concept sector has seen a short-term surge
